Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 vs Pembrolizumab in Advanced Non-Small Cell Lung Cancer
NCT07222566Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Bispecific Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of PF-08634404 in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jan 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07222566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222566.